Keryx Biopharmaceuticals to Present at the 24th Annual Oppenheimer Healthcare Conference

Keryx Biopharmaceuticals to Present at the 24th Annual Oppenheimer Healthcare

Presentation Scheduled for Wednesday, December 11th at 2:10 p.m. ET

NEW YORK, Dec. 9, 2013 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc.
(Nasdaq:KERX) today announced that Ron Bentsur, the Company's Chief Executive
Officer, will be presenting at the 24^th Annual Oppenheimer Healthcare
Conference, being held on Wednesday, December 11^th, in New York City. Mr.
Bentsur's presentation is scheduled to begin at 2:10 pm ET.

A live audio webcast of Mr. Bentsur's presentation will be accessible within
the Media section of the Company's Website at An archived version of this
webcast will be available following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and
commercialization of medically important pharmaceutical products for the
treatment of renal disease. Keryx is developing Zerenex (ferric citrate
coordination complex), an oral, ferric iron-based compound. Keryx has
completed a U.S.-based Phase 3 clinical program for Zerenex for the treatment
of hyperphosphatemia (elevated phosphate levels) in patients with chronic
kidney disease on dialysis, conducted pursuant to a Special Protocol
Assessment (SPA) agreement with the Food and Drug Administration (FDA).The
Company's New Drug Application (NDA) is currently under review by the FDA with
an assigned Prescription Drug User Fee Act (PDUFA) goal date of June 7,
2014.The Marketing Authorization Application filing with the European
Medicines Agency (EMA) is pending submission.The Company is also developing
Zerenex in the U.S. for the management of elevated phosphorus and iron
deficiency anemia in patients with Stage 3 to 5 non-dialysis dependent chronic
kidney disease. In addition, Keryx's Japanese partner, Japan Tobacco Inc. and
Torii Pharmaceutical Co., Ltd. has filed its New Drug Application for
marketing approval of ferric citrate in Japan for the treatment of
hyperphosphatemia in patients with chronic kidney disease. Keryx is
headquartered in New York City.

         Lauren Fischer
         Director - Investor Relations
         Keryx Biopharmaceuticals, Inc.
         Tel: 212.531.5965

Keryx Logo
Press spacebar to pause and continue. Press esc to stop.